- Home
- SRAD vs BLCO Comparison
SRAD vs BLCO Comparison
Compare SRAD & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRAD | BLCO |
|---|---|---|
| Founded | 2001 | 1853 |
| Country | Switzerland | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Ophthalmic Goods |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 6.0B |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | SRAD | BLCO |
|---|---|---|
| Price | $18.40 | $16.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 12 |
| Target Price | ★ $30.18 | $18.55 |
| AVG Volume (30 Days) | ★ 2.2M | 454.5K |
| Earning Date | 01-01-0001 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,101,000,000.00 |
| Revenue This Year | $24.65 | $8.61 |
| Revenue Next Year | $15.05 | $5.52 |
| P/E Ratio | $49.48 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $15.73 | $10.45 |
| 52 Week High | $32.22 | $18.92 |
Technical Indicators
Market Signals| Indicator | SRAD | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 50.57 | 41.12 |
| Support Level | $15.73 | $16.35 |
| Resistance Level | $19.67 | $17.44 |
| Average True Range (ATR) | 0.86 | 0.58 |
| MACD | 0.24 | -0.13 |
| Stochastic Oscillator | 59.26 | 27.39 |
Price Performance
Historical ComparisonAbout SRAD Sportradar Group AG
Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.